Christian Carlos. Peninsula 360 Press [P360P].
After two months of sample collection and results sampling, the pharmaceutical company Pfizer raised from 90 percent to 95 percent the efficacy of its vaccine against SARS-CoV-2, the new coronavirus that causes the disease COVID-19, which, according to statistical data recently compiled by NBC, has left the United States with more than 250 unfortunate deaths.
On Monday, Nov. 9, it was announced that Pfizer's vaccine, in conjunction with the German firm BioNTech, was only 90 percent effective; however, both companies warned that, once the required studies were completed, there was a high probability that its final efficacy would be different.
The Food and Drug Administration (FDA) would approve its emergency use in the next few days; if so, it would be the first vaccine on the market to combat the COVID-19 pandemic. Pfizer's vaccine is in the third phase of clinical trials.
To reach 95 percent effectiveness, more than 43,000 volunteers were required, the pharmaceutical company conducted tests where the FDA imposed a limit of up to 170 infections by COVID-19; of these, 162 corresponded to a dose of placebo and only 8 people were not effective in the vaccine.
It should be noted that the vaccine is up to 94 percent effective in people over the age of 65. Regarding the side effects of the vaccine, Pfizer points out that: "The data show that the vaccine was well tolerated (?) no serious safety problems were observed; the only third-degree adverse event, with a frequency of more than 2%, were cases of fatigue in 3.8% and headache in 2.0%".
In the statement explains: "The primary efficacy analysis demonstrates that BNT162b2 - the vaccine lot - has 95% efficacy against COVID-19 from 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 volunteers in the placebo group versus 8 in the vaccine group.
It should be noted that just this Monday, it was announced that the vaccine developed by Moderna reached an effectiveness of 94.5%; however, compared to the vaccine developed by Pfizer, it showed the same effectiveness in cases where patients had already been infected with the SARS-CoV-2 virus.
However, Moderna has to go through FDA approval after two satisfactory months of testing for its emergency introduction, a process that Pfizer has completed.
Finally, Pfizer expects its formula to be replicated internationally, stating that they "expect to produce up to 50 million doses of vaccine globally by 2020 and up to 1.3 billion doses by the end of 2021".
My brother suggested I might like this blog. He was entirely right. This post actually made my day. You can not imagine simply how much time I had spent for this information! Thanks!